www.seikagaku.co.jp
Assay Development and Screening Partner
Seikagaku Corporation today entered into a collaboration to identify small molecule therapeutics for inflammatory diseases. Evotec will apply its world leading skills in assay development and ultra-high throughput screening (uHTS) to rapidly identify biologically active compounds from its corporate library that interact with selected disease targets of Seikagaku. Active compounds identified in screening will be further characterised and prioritised by Evotec for progression into subsequent lead optimization programs.
"Due to its expertise and wealth of experience in screening a variety of drug targets to highest quality standards we have identified Evotec as our preferred partner in this discipline."
Mr. Shirow Enoki, President, Seikagaku